525 related articles for article (PubMed ID: 23364255)
1. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
[TBL] [Abstract][Full Text] [Related]
2. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome.
Gao Y; Jia ZM; Sun YJ; Zhang ZH; Ren LN; Qi GX
Chin Med J (Engl); 2012 Jul; 125(13):2250-4. PubMed ID: 22882843
[TBL] [Abstract][Full Text] [Related]
3. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
[TBL] [Abstract][Full Text] [Related]
4. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
Sardella G; Lucisano L; Mancone M; Conti G; Calcagno S; Stio RE; Pennacchi M; Biondi-Zoccai G; Canali E; Fedele F
Int J Cardiol; 2013 Oct; 168(4):3715-20. PubMed ID: 23849964
[TBL] [Abstract][Full Text] [Related]
5. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
Patti G; Pasceri V; Colonna G; Miglionico M; Fischetti D; Sardella G; Montinaro A; Di Sciascio G
J Am Coll Cardiol; 2007 Mar; 49(12):1272-8. PubMed ID: 17394957
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY Study).
Ko YG; Won H; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Bae JH; Lee S; Lim DS; Jang Y
Am J Cardiol; 2014 Jul; 114(1):29-35. PubMed ID: 24831577
[TBL] [Abstract][Full Text] [Related]
8. Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study).
Veselka J; Hájek P; Tomašov P; Tesař D; Brůhová H; Matějovič M; Branny M; Studenčan M; Zemánek D
Am J Cardiol; 2014 Feb; 113(3):446-51. PubMed ID: 24304551
[TBL] [Abstract][Full Text] [Related]
9. 12-month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome.
Yun KH; Oh SK; Rhee SJ; Yoo NJ; Kim NH; Jeong JW
Int J Cardiol; 2011 Jan; 146(1):68-72. PubMed ID: 20471117
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
Sardella G; Conti G; Donahue M; Mancone M; Canali E; De Carlo C; Di Roma A; Calcagno S; Lucisano L; Fedele F
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E36-43. PubMed ID: 22517610
[TBL] [Abstract][Full Text] [Related]
11. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
Leoncini M; Toso A; Maioli M; Tropeano F; Badia T; Villani S; Bellandi F
Am Heart J; 2014 Nov; 168(5):792-7. PubMed ID: 25440809
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention.
Jiao Y; Hu F; Zhang Z; Gong K; Sun X; Li A; Liu N
Clin Drug Investig; 2015 Dec; 35(12):777-84. PubMed ID: 26387028
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin may reduce the incidence of cardiovascular events in patients with acute coronary syndromes receiving percutaneous coronary intervention by suppressing miR-155/SHIP-1 signaling pathway.
Xie W; Li P; Wang Z; Chen J; Lin Z; Liang X; Mo Y
Cardiovasc Ther; 2014 Dec; 32(6):276-82. PubMed ID: 25319951
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Yun KH; Shin SN; Ko JS; Rhee SJ; Kim NH; Oh SK; Jeong JW
J Cardiol; 2012 Nov; 60(5):383-8. PubMed ID: 22884684
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
[TBL] [Abstract][Full Text] [Related]
16. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial.
Mannacio VA; Iorio D; De Amicis V; Di Lello F; Musumeci F
J Thorac Cardiovasc Surg; 2008 Dec; 136(6):1541-8. PubMed ID: 19114204
[TBL] [Abstract][Full Text] [Related]
17. The effects and mechanisms of high loading dose rosuvastatin therapy before percutaneous coronary intervention in patients with acute coronary syndrome.
Luo J; Li J; Shen X; Hu X; Fang Z; Lv X; Zhou S
Int J Cardiol; 2013 Sep; 167(5):2350-3. PubMed ID: 23194788
[No Abstract] [Full Text] [Related]
18. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
[TBL] [Abstract][Full Text] [Related]
19. Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention.
Gordin J; Haider A; Swaminathan RV; Kim LK; Minutello RM; Bergman G; Wong SC; Feldman DN
Am J Cardiol; 2012 Nov; 110(10):1397-404. PubMed ID: 22858186
[TBL] [Abstract][Full Text] [Related]
20. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Ridker PM; MacFadyen J; Libby P; Glynn RJ
Am J Cardiol; 2010 Jul; 106(2):204-9. PubMed ID: 20599004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
